
AiCuris specializes in developing targeted antiviral therapies for immunocompromised patients, focusing on life‑threatening infections such as cytomegalovirus and herpes simplex virus. Its flagship product, PREVYMIS, co‑marketed with MSD, is approved for CMV prophylaxis in transplant recipients, while the phase‑III candidate Pritelivir addresses recurrent and resistant HSV in a broad immunocompromised cohort. Leveraging deep expertise in virology and a robust pre‑clinical and clinical development pipeline, AiCuris delivers precision medicines that improve outcomes for high‑risk patients. The company’s culture is rooted in a commitment to innovation, rigorous science, and partnership with leading pharma to bring life‑saving solutions to market.
The Senior Director of Medical Affairs will drive medical affairs excellence and oversee the field-based Medical Science Liaison team, vendor partnerships, and comprehensive medical communications functions. This role will play a critical role in assisting the development and tactical execution of the medical affair's strategic goals for the 2026 launch of pritelivir.
AiCuris specializes in developing targeted antiviral therapies for immunocompromised patients, focusing on life‑threatening infections such as cytomegalovirus and herpes simplex virus. Its flagship product, PREVYMIS, co‑marketed with MSD, is approved for CMV prophylaxis in transplant recipients, while the phase‑III candidate Pritelivir addresses recurrent and resistant HSV in a broad immunocompromised cohort. Leveraging deep expertise in virology and a robust pre‑clinical and clinical development pipeline, AiCuris delivers precision medicines that improve outcomes for high‑risk patients. The company’s culture is rooted in a commitment to innovation, rigorous science, and partnership with leading pharma to bring life‑saving solutions to market.